Pre Exposure Prophylaxis clinical trials

Explore recruiting pre exposure prophylaxis clinical trials.

Recruiting pre exposure prophylaxis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pre Exposure Prophylaxis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label pilot study to assess pain experience and usability of different injection techniques and devices for the administration of the purified chick-embryo cell-culture rabies vaccine in children aged 4 to 14 years

Belgium

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment

Spain, France, Germany, Poland, Belgium, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Persistence, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for HIV Pre-Exposure Prophylaxis (PrEP) in People Who Would Benefit from PrEP

France

Phase II and Phase III (Integrated) EU CTIS Study details

SIRAVA: Five-year boostability after single-visit single-dose intramuscular rabies pre-exposure prophylaxis

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection.

Italy, Denmark, Spain, France, Austria, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Impact of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis persistence and coverage in men who have sex with men in France: a randomized controlled clinical trial.

France

Phase III and phase IV (Integrated) EU CTIS Study details

Pre Exposure Prophylaxis trials by city

Pre Exposure Prophylaxis in Toronto Pre Exposure Prophylaxis in Vancouver Pre Exposure Prophylaxis in Montreal Pre Exposure Prophylaxis in Calgary Pre Exposure Prophylaxis in Edmonton Pre Exposure Prophylaxis in Ottawa Pre Exposure Prophylaxis in Winnipeg Pre Exposure Prophylaxis in Quebec City Pre Exposure Prophylaxis in Hamilton Pre Exposure Prophylaxis in Kitchener Pre Exposure Prophylaxis in London Pre Exposure Prophylaxis in Halifax Pre Exposure Prophylaxis in New York Pre Exposure Prophylaxis in Los Angeles Pre Exposure Prophylaxis in Chicago Pre Exposure Prophylaxis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease